http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#Head http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#assertion http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#provenance http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#pubInfo http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#assertion http://purl.obolibrary.org/obo/MONDO_0005689 http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Disease http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/MONDO_0005689 http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/DRUGBANK:DB00289 http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association http://www.w3.org/2000/01/rdf-schema#label Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature. http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association https://w3id.org/biolink/vocab/has_population_context http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#context http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association https://w3id.org/biolink/vocab/publications https://pubmed.ncbi.nlm.nih.gov/32227801 http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/OffLabelIndication http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#context http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Cohort http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#context http://www.w3.org/2000/01/rdf-schema#label Adults https://identifiers.org/DRUGBANK:DB00289 http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Drug http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#provenance http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#assertion http://www.w3.org/ns/prov#generatedAtTime 2021-08-24T19:10:17.198466 http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#pubInfo http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#sig http://purl.org/nanopub/x/hasSignature FVwJfIjALf5/MYIjLXomxV1cXUmlzeawYOyfcbCtwM3gBFhTHpyOhXCT3VmCIB1Y+4vAIvqxWggp5fJbESYM3AlyX8nnbHIsmK8IjL0ljpuPY8M+uslp/85zU4EIxNJw/m8t2T7R9HEI87Osifg9AL4RKA0cqDPT9IBRgfjKmZM= http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g http://www.w3.org/ns/prov#generatedAtTime 2021-08-24T19:10:17.198466 http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RArHvzwBUeWXELeFKKo8xrH95ArEY-xIwwIKLWGFBUm3g https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY